ArticleFrontiers in microbiology2019
Synergistic Activity of Fosfomycin, Ciprofloxacin, and Gentamicin Against
Article in Frontiers in microbiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
47 citing papers in PubMed, 78 citations in OpenAlex.
- Dual Release of Antibiotics with Additive Effect from Cleavable Hydrogels Based on Amino/Thiol-Yne Click Chemistry.Biomacromolecules · 2026Article
- [Antimicrobial therapy of periprosthetic joint infection : Full version of the AE guidelines (2026)].Orthopadie (Heidelberg, Germany) · 2026Review
- Decoding resistance: a comprehensive study on pathogens and antibiotic efficacy in periprosthetic joint infections.Journal of orthopaedic surgery and research · 2026Article
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Cranberry juice potentiates sensitivity of uropathogenicApplied and environmental microbiology · 2026Article
- Synergistic Antimicrobial and Antibiofilm Activity of Nitroxoline in Combination with Hydroquinone Against UropathogenicAntibiotics (Basel, Switzerland) · 2026Article
- Reviving Old Antibiotics: New Indications and Therapeutic Perspectives-A Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Emerging Multimodal Strategies for Bacterial Biofilm Eradication: A Comprehensive Review.Microorganisms · 2025Review
- Combination Antibiotic Therapy for Orthopedic Infections.Antibiotics (Basel, Switzerland) · 2025Review
- Emerging Concepts for the Treatment of Biofilm-Associated Bone and Joint Infections with IV Fosfomycin: A Literature Review.Microorganisms · 2025Review
- Functionalized zeolite regulates bone metabolic microenvironment.Materials today. Bio · 2025Review
- Antimicrobial susceptibilities of clinical bacterial isolates from urinary tract infections to fosfomycin and comparator antibiotics determined by agar dilution method and automated micro broth dilution.Microbiology spectrum · 2025Article
- Controlling Oral Polymicrobial Biofilm Using Usnic Acid on the Surface of Titanium in the Artificial Saliva Media.Antibiotics (Basel, Switzerland) · 2025Article
- Overcoming the drug resistance barrier: progress in fosfomycin combination therapy against multidrug-resistant pathogens.Frontiers in microbiology · 2025Review
- Fluoroquinolones and Biofilm: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Patterning Bacterial Cells on Quasi-Liquid Surfaces for Biofilm Morphological Control.Advanced functional materials · 2024Article
- Combinatory Effect of Nitroxoline and Gentamicin in the Control of Uropathogenic Enterococci Infections.Antibiotics (Basel, Switzerland) · 2024Article
- A Newly Incompatibility F Replicon Allele (FIB81) in Extensively Drug-ResistantInternational journal of molecular sciences · 2024Article
- In Vitro Antibiofilm Activity of Fosfomycin Alone and in Combination with Other Antibiotics against Multidrug-Resistant and Extensively Drug-ResistantPharmaceuticals (Basel, Switzerland) · 2024Article
- From Polymeric Nanoformulations to Polyphenols-Strategies for Enhancing the Efficacy and Drug Delivery of Gentamicin.Antibiotics (Basel, Switzerland) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gram-negative (GN) rods cause about 10% periprosthetic joint infection (PJI) and represent an increasing challenge due to emergence of antimicrobial resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.